Coyne Scientific

Coyne Scientific was a private biotech services company focused on helping pharmaceutical and other chemical-product companies evaluate safety and toxicity using in vitro assays built on human induced pluripotent stem cells from genetically diverse donor cohorts. Its approach was designed to estimate the range and distribution of human responses to drugs or other agents across a target population, effectively supporting “clinical trials in a dish” style safety assessment. The company appears to have operated as a service and platform business rather than a therapeutic drug developer, with intellectual property around predictive response, toxicity, and stimulus-response testing methods. Public web evidence indicates the business later became inactive, with bankruptcy proceedings in 2017 and Georgia registry status showing revoked.